AR111764A1 - Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas - Google Patents
Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadasInfo
- Publication number
- AR111764A1 AR111764A1 ARP180101401A ARP180101401A AR111764A1 AR 111764 A1 AR111764 A1 AR 111764A1 AR P180101401 A ARP180101401 A AR P180101401A AR P180101401 A ARP180101401 A AR P180101401A AR 111764 A1 AR111764 A1 AR 111764A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- variable region
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 10
- 102000015696 Interleukins Human genes 0.000 abstract 1
- 108010063738 Interleukins Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una proteína de unión a antígeno que comprende una región variable de cadena pesada que tiene la secuencia de aminoácidos CDRH1 que se muestra en la SEQ ID Nº 5, la secuencia de aminoácidos CDRH2 que se muestra en la SEQ ID Nº 6, y la secuencia de aminoácidos CDRH3 que se muestra en la SEQ ID Nº 7; y una región variable de cadena ligera que tiene la secuencia de aminoácidos CDRL1 mostrada en la SEQ ID Nº 8, la secuencia de aminoácidos CDRL2 que se muestra en la SEQ ID Nº 9, y la secuencia de aminoácidos CDRL3 que se muestra en la SEQ ID Nº 10; o bien comprende una secuencia de la región variable de la cadena pesada que tiene la secuencia de aminoácidos mostrada en la SEQ ID Nº 3; y una secuencia de la región variable de la cadena ligera que tiene la secuencia de aminoácidos mostrada en la SEQ ID Nº 4. Un anticuerpo que comprende una cadena pesada y una cadena ligera, que comprende la proteína de la reivindicación 1 o la reivindicación 4; o que comprende una cadena pesada que tiene la secuencia de aminoácidos mostrada en la SEQ ID Nº 1 y una cadena ligera que tiene la secuencia de aminoácidos mostrada en SEQ ID Nº 2. Una cadena peptídica comprendida en el anticuerpo que comprende la secuencia de aminoácidos mostrada en la SEQ ID Nº 3 o en la SEQ ID Nº 1. Composiciones relacionadas para el tratamiento de enfermedades mediadas por interleucina 5 (IL-5).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511441P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR111764A1 true AR111764A1 (es) | 2019-08-14 |
Family
ID=62683386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180101401A AR111764A1 (es) | 2017-05-26 | 2018-05-24 | Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10787509B2 (es) |
| EP (1) | EP3630824A1 (es) |
| JP (2) | JP7224304B2 (es) |
| KR (1) | KR102473898B1 (es) |
| CN (5) | CN117018190A (es) |
| AR (1) | AR111764A1 (es) |
| AU (2) | AU2018273174B2 (es) |
| BR (1) | BR112019024884A2 (es) |
| CA (1) | CA3064522A1 (es) |
| CL (1) | CL2019003418A1 (es) |
| CO (1) | CO2019013245A2 (es) |
| CR (1) | CR20190541A (es) |
| DO (1) | DOP2019000297A (es) |
| EA (1) | EA201992802A1 (es) |
| IL (1) | IL270719B2 (es) |
| MX (1) | MX2019014105A (es) |
| MY (1) | MY200912A (es) |
| NZ (1) | NZ760380A (es) |
| PE (1) | PE20191844A1 (es) |
| PH (1) | PH12019502619A1 (es) |
| SG (1) | SG10201913497XA (es) |
| TW (1) | TWI799417B (es) |
| UY (1) | UY37747A (es) |
| WO (1) | WO2018215964A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018273174B2 (en) | 2017-05-26 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and related methods |
| WO2019224724A1 (en) * | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions comprising antibody variants |
| CN111303284A (zh) * | 2018-12-12 | 2020-06-19 | 尚华科创投资管理（江苏）有限公司 | 抗人白细胞介素5(il-5)单克隆抗体及其应用 |
| WO2022136209A1 (en) | 2020-12-22 | 2022-06-30 | Glaxosmithkline Intellectual Property Development Limited | Interleukin 5 binding protein dosage regimen |
| EP4267184B1 (en) * | 2020-12-22 | 2025-11-26 | GlaxoSmithKline Intellectual Property Development Limited | Interleukin 5 binding protein dosage regimen |
| CA3239667A1 (en) | 2021-12-03 | 2023-06-08 | Glaxosmithkline Intellectual Property Development Limited | Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, hypereosinophilic syndrome chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp |
| WO2025238121A1 (en) | 2024-05-17 | 2025-11-20 | Glaxosmithkline Intellectual Property Development Limited | Anti-il-5 antibody in the treatment of asthma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5683892A (en) | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| EP0800536B1 (en) * | 1994-12-23 | 2006-11-29 | Smithkline Beecham Corporation | Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders |
| AU2008201419C1 (en) * | 2000-12-12 | 2018-01-18 | Board Of Regents, The University Of Texas System | Molecules with extended half-lives, compositions and uses thereof |
| EP2606906A1 (en) | 2007-04-30 | 2013-06-26 | GlaxoSmithKline LLC | Methods for administering anti-IL-5 antibodies |
| CA2719786A1 (en) | 2008-03-28 | 2009-10-01 | Glaxosmithkline Llc | Methods of treatment |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| PT2654790T (pt) * | 2010-12-22 | 2019-05-16 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpo modificado com semivida melhorada |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| KR20240099511A (ko) | 2015-08-24 | 2024-06-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 생물제약 조성물 |
| EA201991552A1 (ru) | 2016-12-23 | 2020-01-09 | Сефалон, Инк. | Анти-il-5 антитела |
| AU2018273174B2 (en) | 2017-05-26 | 2021-10-14 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions and related methods |
| WO2019224724A1 (en) * | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Biopharmaceutical compositions comprising antibody variants |
-
2018
- 2018-05-24 AU AU2018273174A patent/AU2018273174B2/en active Active
- 2018-05-24 EP EP18732488.4A patent/EP3630824A1/en active Pending
- 2018-05-24 CN CN202311013988.0A patent/CN117018190A/zh active Pending
- 2018-05-24 JP JP2019565279A patent/JP7224304B2/ja active Active
- 2018-05-24 NZ NZ760380A patent/NZ760380A/en unknown
- 2018-05-24 BR BR112019024884-6A patent/BR112019024884A2/pt unknown
- 2018-05-24 PE PE2019002461A patent/PE20191844A1/es unknown
- 2018-05-24 UY UY0001037747A patent/UY37747A/es unknown
- 2018-05-24 CA CA3064522A patent/CA3064522A1/en active Pending
- 2018-05-24 KR KR1020197037587A patent/KR102473898B1/ko active Active
- 2018-05-24 CN CN201880046323.0A patent/CN110891968B/zh active Active
- 2018-05-24 CN CN202311013609.8A patent/CN117018189A/zh active Pending
- 2018-05-24 IL IL270719A patent/IL270719B2/en unknown
- 2018-05-24 CR CR20190541A patent/CR20190541A/es unknown
- 2018-05-24 TW TW107117675A patent/TWI799417B/zh active
- 2018-05-24 US US15/987,942 patent/US10787509B2/en active Active
- 2018-05-24 AR ARP180101401A patent/AR111764A1/es unknown
- 2018-05-24 MX MX2019014105A patent/MX2019014105A/es unknown
- 2018-05-24 CN CN202311014554.2A patent/CN117100853A/zh active Pending
- 2018-05-24 CN CN202311013236.4A patent/CN117018188A/zh active Pending
- 2018-05-24 WO PCT/IB2018/053683 patent/WO2018215964A1/en not_active Ceased
- 2018-05-24 SG SG10201913497XA patent/SG10201913497XA/en unknown
- 2018-05-24 MY MYPI2019006883A patent/MY200912A/en unknown
- 2018-05-24 EA EA201992802A patent/EA201992802A1/ru unknown
-
2019
- 2019-11-21 PH PH12019502619A patent/PH12019502619A1/en unknown
- 2019-11-22 CL CL2019003418A patent/CL2019003418A1/es unknown
- 2019-11-22 DO DO2019000297A patent/DOP2019000297A/es unknown
- 2019-11-26 CO CONC2019/0013245A patent/CO2019013245A2/es unknown
-
2020
- 2020-08-07 US US16/988,257 patent/US11976113B2/en active Active
-
2021
- 2021-09-17 AU AU2021232807A patent/AU2021232807A1/en not_active Abandoned
-
2023
- 2023-01-31 JP JP2023013628A patent/JP7521022B2/ja active Active
-
2024
- 2024-03-22 US US18/613,481 patent/US20240417456A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111764A1 (es) | Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas | |
| PE20161033A1 (es) | Proteinas de union al antigeno gitr | |
| ES2517420T3 (es) | Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos | |
| CO2020014727A2 (es) | Anticuerpo anti proteína reguladora de señales alfa sirpαlfa | |
| PE20230415A1 (es) | ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2) | |
| IL257281A (en) | Anti-pd-1 antibodies and methods of using them | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| ES2430068T3 (es) | Proteínas de unión a antígeno del factor de crecimiento de tipo factor de crecimiento epidérmico de unión a heparina | |
| PE20181270A1 (es) | Anticuerpo que neutraliza el virus respiratorio sincitial humano | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
| IL259940B2 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| JP2020500538A5 (es) | ||
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| AR096687A1 (es) | Anticuerpos anti-fcrh5 | |
| AR086579A1 (es) | Proteinas de union a antigeno | |
| PE20131400A1 (es) | Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9) | |
| WO2012045481A3 (en) | Antibody targeting osteoclast-related protein siglec-15 | |
| ES2670621T3 (es) | Anticuerpos que se unen a OX40 y sus usos | |
| PE20161439A1 (es) | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos | |
| AR082194A1 (es) | Anticuerpos anti-ron | |
| BR112015027587A2 (pt) | Anticorpos anti-vegf e uso dos mesmos | |
| WO2014144542A3 (en) | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same | |
| PE20161221A1 (es) | Anticuerpos de il-21 |